Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.

Background: Anticonvulsants are used for pre-eclampsia in the belief they prevent eclamptic convulsions, and so improve outcome. Evidence supported magnesium sulphate as the drug to evaluate.Methods: Eligible women (n=10141) had not given birth or were 24 h or less postpartum; blood pressure of 140/...

Descripción completa

Detalles Bibliográficos
Publicado en:Lancet Vol. 359; no. 9321; pp. 1877 - 1891
Autores principales: Altman, Douglas, Carroli, Guillermo, Duley, Lelia, Farrell, Barbara, Moodley, Jack, Neilson, James, Smith, David
Formato: clinical trial research randomized controlled trial Journal Article
Publicado: Lancet 6/1/2002
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=119541193&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 119541193
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01406736
        LAN
      jtl: Lancet
      issn: 01406736
      maglogo: N
    pubinfo:
      dt: 6/1/2002
      vid: 359
      iid: 9321
      pid: 1297
      pub: Lancet
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        119541193
        NLM12057549
        119541193
        10.1016/S0140-6736(02)08778-0
        NLM12057549
        119541193
      ppf: 1877
      ppct: 14
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.
      aug:
        au:
          Altman, Douglas
          Carroli, Guillermo
          Duley, Lelia
          Farrell, Barbara
          Moodley, Jack
          Neilson, James
          Smith, David
      sug:
        subj:
          Magnesium Sulfate Therapeutic Use
          Perinatal Death
          Pre-Eclampsia Prevention and Control
          Anticonvulsants Therapeutic Use
          Pregnancy
          Treatment Outcomes
          Anticonvulsants Adverse Effects
          Gestational Age
          Blood Pressure
          Maternal Mortality
          Human
          Cause of Death
          Pre-Eclampsia Diagnosis
          Magnesium Sulfate Adverse Effects
          Pre-Eclampsia Drug Therapy
          Infant, Newborn
          Female
          Clinical Trials
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Randomized Controlled Trials
          Questionnaires
          Scales
          Short Portable Mental Status Questionnaire
          Infant, Newborn: birth-1 month
          Female
      ab: Background: Anticonvulsants are used for pre-eclampsia in the belief they prevent eclamptic convulsions, and so improve outcome. Evidence supported magnesium sulphate as the drug to evaluate.Methods: Eligible women (n=10141) had not given birth or were 24 h or less postpartum; blood pressure of 140/90 mm Hg or more, and proteinuria of 1+ (30 mg/dL) or more; and there was clinical uncertainty about magnesium sulphate. Women were randomised in 33 countries to either magnesium sulphate (n=5071) or placebo (n=5070). Primary outcomes were eclampsia and, for women randomised before delivery, death of the baby. Follow up was until discharge from hospital after delivery. Analyses were by intention to treat.Findings: Follow-up data were available for 10,110 (99.7%) women, 9992 (99%) of whom received the allocated treatment. 1201 of 4999 (24%) women given magnesium sulphate reported side-effects versus 228 of 4993 (5%) given placebo. Women allocated magnesium sulphate had a 58% lower risk of eclampsia (95% CI 40-71) than those allocated placebo (40, 0.8%, vs 96, 1.9%; 11 fewer women with eclampsia per 1000 women). Maternal mortality was also lower among women allocated magnesium sulphate (relative risk 0.55, 0.26-1.14). For women randomised before delivery, there was no clear difference in the risk of the baby dying (576, 12.7%, vs 558, 12.4%; relative risk 1.02, 99% CI 0.92-1.14). The only notable difference in maternal or neonatal morbidity was for placental abruption (relative risk 0.67, 99% CI 0.45-0.89).Interpretation: Magnesium sulphate halves the risk of eclampsia, and probably reduces the risk of maternal death. There do not appear to be substantive harmful effects to mother or baby in the short term.
      pubtype: Academic Journal
      doctype:
        clinical trial
        research
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N